Current treatment options for colon cancer peritoneal carcinomatosis

World Journal of Gastroenterology

Volumn 20, Issue 35, 2014, Pages 12493-12500

  Aoyagi, Tomoyoshi ^a   Terracina, Krista P ^a   Raza, Ali ^a   Takabe, Kazuaki ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer; Carcinomatosis; Colorectal; Cytoreductive surgery; Hyperthermic intraperitoneal chemotherapy; Intraperitoneal chemotherapy; Mechanism; Peritoneal

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURGERY; CARCINOMATOUS PERITONITIS; COLON CANCER; CYTOREDUCTIVE SURGERY; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; INTRAPERITONEAL CHEMOTHERAPY; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; PERITONEAL CAVITY; REVIEW; SYSTEMIC CIRCULATION; TUMOR INVASION; ADJUVANT CHEMOTHERAPY; ADVERSE EFFECTS; CARCINOMA; COLON TUMOR; DRUG ADMINISTRATION; INDUCED HYPOTHERMIA; INFUSION; MORTALITY; PATHOLOGY; PERITONEAL NEOPLASMS; SECONDARY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; CYTOREDUCTION SURGICAL PROCEDURES; DRUG ADMINISTRATION SCHEDULE; HUMANS; HYPOTHERMIA, INDUCED; INFUSIONS, PARENTERAL; PERITONEAL NEOPLASMS; TREATMENT OUTCOME;

EID: 84909592446     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i35.12493     Document Type: Review

References (80)

1. House MG, Ito H, Gönen M, Fong Y, Allen PJ, DeMatteo RP, Brennan MF, Blumgart LH, Jarnagin WR, D'Angelica MI. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg 2010; 210: 744-752, 752-755 [PMID: 20421043 DOI: 10.1016/j.jamcollsurg.2009.12.040]
2. Kanas GP, Taylor A, Primrose JN, Langeberg WJ, Kelsh MA, Mowat FS, Alexander DD, Choti MA, Poston G. Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol 2012; 4: 283-301 [PMID: 23152705 DOI: 10.2147/CLEP.S34285]
3. Spolverato G, Ejaz A, Azad N, Pawlik TM. Surgery for colorectal liver metastases: The evolution of determining prognosis. World J Gastrointest Oncol 2013; 5: 207-221 [PMID: 24363829 DOI: 10.4251/wjgo.v5.i12.207]
4. Go PH, Klaassen Z, Meadows MC, Chamberlain RS. Gastrointestinal cancer and brain metastasis: a rare and ominous sign. Cancer 2011; 117: 3630-3640 [PMID: 21319152 DOI: 10.1002/cncr.25940]
5. Villeneuve PJ, Sundaresan RS. Surgical management of colorectal lung metastasis. Clin Colon Rectal Surg 2009; 22: 233-241 [PMID: 21037814 DOI: 10.1055/s-0029-1242463]
6. Li WH, Peng JJ, Xiang JQ, Chen W, Cai SJ, Zhang W. Oncological outcome of unresectable lung metastases without extrapulmonary metastases in colorectal cancer. World J Gastroenterol 2010; 16: 3318-3324 [PMID: 20614489]
7. Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JW, de Hingh IH. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer 2011; 128: 2717-2725 [PMID: 20715167 DOI: 10.1002/ijc.25596]
8. Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg 2012; 99: 699-705 [PMID: 22287157 DOI: 10.1002/bjs.8679]
9. Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002; 89: 1545-1550 [PMID: 12445064 DOI: 10.1046/j.1365-2168.2002.02274.x]
10. Minsky BD, Mies C, Rich TA, Recht A, Chaffey JT. Potentially curative surgery of colon cancer: patterns of failure and survival. J Clin Oncol 1988; 6: 106-118 [PMID: 2826711]
11. Russell AH, Tong D, Dawson LE, Wisbeck WM, Griffin TW, Laramore GE, Luk KH. Adenocarcinoma of the retroperitoneal ascending and descending colon: sites of initial dissemination and clinical patterns of recurrence following surgery alone. Int J Radiat Oncol Biol Phys 1983; 9: 361-365 [PMID: 6841189]
12. Tong D, Russell AH, Dawson LE, Wisbeck WM, Griffin TW, Laramore GE, Luk KH. Adenocarcinoma of the cecum: natural history and clinical patterns of recurrence following radical surgery. Int J Radiat Oncol Biol Phys 1983; 9: 357-360 [PMID: 6841188]
13. Sadeghi B, Arvieux C, Glehen O, Beaujard AC, Rivoire M, Baulieux J, Fontaumard E, Brachet A, Caillot JL, Faure JL, Porcheron J, Peix JL, Franc¸ois Y, Vignal J, Gilly FN. Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study. Cancer 2000; 88: 358-363 [PMID: 10640968]
14. Elias D, Blot F, El Otmany A, Antoun S, Lasser P, Boige V, Rougier P, Ducreux M. Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy. Cancer 2001; 92: 71-76 [PMID: 11443611]
15. Sugarbaker PH. Surgical management of carcinomatosis from colorectal cancer. Clin Colon Rectal Surg 2005; 18: 190-203 [PMID: 20011302 DOI: 10.1055/s-2005-916280]
16. Fiori E, Lamazza A, De Cesare A, Bononi M, Volpino P, Schillaci A, Cavallaro A, Cangemi V. Palliative management of malignant rectosigmoidal obstruction. Colostomy vs. endoscopic stenting. A randomized prospective trial. Anticancer Res 2004; 24: 265-268 [PMID: 15015606]
17. Sugarbaker PH. Review of a personal experience in the management of carcinomatosis and sarcomatosis. Jpn J Clin Oncol 2001; 31: 573-583 [PMID: 11902487]
18. Blair SL, Chu DZ, Schwarz RE. Outcome of palliative operations for malignant bowel obstruction in patients with peritoneal carcinomatosis from nongynecological cancer. Ann Surg Oncol 2001; 8: 632-637 [PMID: 11569777]
19. Ceelen WP, Flessner MF. Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence. Nat Rev Clin Oncol 2010; 7: 108-115 [PMID: 20010898 DOI: 10.1038/nrclinonc.2009.217]
20. Piso P, Arnold D. Multimodal treatment approaches for peritoneal carcinosis in colorectal cancer. Dtsch Arztebl Int 2011; 108: 802-808 [PMID: 22190994 DOI: 10.3238/arztebl.2011.0802]
21. Berthelot C, Morel O, Girault S, Verrièle V, Poirier AL, Moroch J, Boucher Y, Le Jeune JJ, Lorimier G. Use of FDG-PET/CT for peritoneal carcinomatosis before hyperthermic intraperitoneal chemotherapy. Nucl Med Commun 2011; 32: 23-29 [PMID: 21042225 DOI: 10.1097/MNM.0b013e328340e730]
22. Yan TD, Morris DL, Shigeki K, Dario B, Marcello D. Preoperative investigations in the management of peritoneal surface malignancy with cytoreductive surgery and perioperative intraperitoneal chemotherapy: Expert consensus statement. J Surg Oncol 2008; 98: 224-227 [PMID: 18726881 DOI: 10.1002/jso.21069]
23. van Gestel YR, Thomassen I, Lemmens VE, Pruijt JF, van Herk-Sukel MP, Rutten HJ, Creemers GJ, de Hingh IH. Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer. Eur J Surg Oncol 2014; 40: 963-969 [PMID: 24183168 DOI: 10.1016/j.ejso.2013.10.001]
24. Galandiuk S, Wieand HS, Moertel CG, Cha SS, Fitzgibbons RJ, Pemberton JH, Wolff BG. Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet 1992; 174: 27-32 [PMID: 1729745]
25. Ceelen WP, Bracke ME. Peritoneal minimal residual disease in colorectal cancer: mechanisms, prevention, and treatment. Lancet Oncol 2009; 10: 72-79 [PMID: 19111247 DOI: 10.1016/S1470-2045(08)70335-8]
26. Ceelen W, Van Nieuwenhove Y, Pattyn P. Surgery and intracavitary chemotherapy for peritoneal carcinomatosis from colorectal origin. Acta Gastroenterol Belg 2008; 71: 373-378 [PMID: 19317277]
27. Terauchi M, Kajiyama H, Yamashita M, Kato M, Tsukamoto H, Umezu T, Hosono S, Yamamoto E, Shibata K, Ino K, Nawa A, Nagasaka T, Kikkawa F. Possible involvement of TWIST in enhanced peritoneal metastasis of epithelial ovarian carcinoma. Clin Exp Metastasis 2007; 24: 329-339 [PMID: 17487558 DOI: 10.1007/s10585-007-9070-1]
28. Kokenyesi R, Murray KP, Benshushan A, Huntley ED, Kao MS. Invasion of interstitial matrix by a novel cell line from primary peritoneal carcinosarcoma, and by established ovarian carcinoma cell lines: role of cell-matrix adhesion molecules, proteinases, and E-cadherin expression. Gynecol Oncol 2003; 89: 60-72 [PMID: 12694655]
29. Pocard M, Debruyne P, Bras-Gonc¸alves R, Mareel M, Dutrillaux B, Poupon MF. Single alteration of p53 or E-cadherin genes can alter the surgical resection benefit in an experimental model of colon cancer. Dis Colon Rectum 2001; 44: 1106-1112 [PMID: 11535849]
30. Hansen E, Wolff N, Knuechel R, Ruschoff J, Hofstaedter F, Taeger K. Tumor cells in blood shed from the surgical field. Arch Surg 1995; 130: 387-393 [PMID: 7710337]
31. Meyers MA. Distribution of intra-abdominal malignant seeding: dependency on dynamics of flow of ascitic fluid. Am J Roentgenol Radium Ther Nucl Med 1973; 119: 198-206 [PMID: 4744725]
32. Sugarbaker PH . Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology. Cancer Treat Res 1996; 82: 79-100 [PMID: 8849945]
33. Jonjić N, Peri G, Bernasconi S, Sciacca FL, Colotta F, Pelicci P, Lanfrancone L, Mantovani A. Expression of adhesion molecules and chemotactic cytokines in cultured human mesothelial cells. J Exp Med 1992; 176: 1165-1174 [PMID: 1383376]
34. Bittinger F, Klein CL, Skarke C, Brochhausen C, Walgenbach S, Röhrig O, Köhler H, Kirkpatrick CJ. PECAM-1 expression in human mesothelial cells: an in vitro study. Pathobiology 1996; 64: 320-327 [PMID: 9159026]
35. van Grevenstein WM, Hofland LJ, van Rossen ME, van Koetsveld PM, Jeekel J, van Eijck CH. Inflammatory cytokines stimulate the adhesion of colon carcinoma cells to mesothelial monolayers. Dig Dis Sci 2007; 52: 2775-2783 [PMID: 17394066 DOI: 10.1007/s10620-007-9778-4]
36. Ziprin P, Ridgway PF, Pfistermüller KL, Peck DH, Darzi AW. ICAM-1 mediated tumor-mesothelial cell adhesion is modulated by IL-6 and TNF-alpha: a potential mechanism by which surgical trauma increases peritoneal metastases. Cell Commun Adhes 2003; 10: 141-154 [PMID: 14668061]
37. van Rossen ME, Hofland LJ, van den Tol MP, van Koetsveld PM, Jeekel J, Marquet RL, van Eijck CH. Effect of inflammatory cytokines and growth factors on tumour cell adhesion to the peritoneum. J Pathol 2001; 193: 530-537 [PMID: 11276014]
38. Klein CL, Bittinger F, Skarke CC, Wagner M, Köhler H, Walgenbach S, Kirkpatrick CJ. Effects of cytokines on the expression of cell adhesion molecules by cultured human omental mesothelial cells. Pathobiology 1995; 63: 204-212 [PMID: 8866792]
39. Cannistra SA, Kansas GS, Niloff J, DeFranzo B, Kim Y, Ottensmeier C. Binding of ovarian cancer cells to peritoneal mesothelium in vitro is partly mediated by CD44H. Cancer Res 1993; 53: 3830-3838 [PMID: 8339295]
40. Gerber SA, Rybalko VY, Bigelow CE, Lugade AA, Foster TH, Frelinger JG, Lord EM. Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. Am J Pathol 2006; 169: 1739-1752 [PMID: 17071597 DOI: 10.2353/ajpath.2006.051222]
41. Heath RM, Jayne DG, O'Leary R, Morrison EE, Guillou PJ. Tumour-induced apoptosis in human mesothelial cells: a mechanism of peritoneal invasion by Fas Ligand/Fas interaction. Br J Cancer 2004; 90: 1437-1442 [PMID: 15054468 DOI: 10.1038/sj.bjc.6601635]
42. Warn R, Harvey P, Warn A, Foley-Comer A, Heldin P, Versnel M, Arakaki N, Daikuhara Y, Laurent GJ, Herrick SE, Mutsaers SE. HGF/SF induces mesothelial cell migration and proliferation by autocrine and paracrine pathways. Exp Cell Res 2001; 267: 258-266 [PMID: 11426944 DOI: 10.1006/excr.2001.5240]
43. Carreiras F, Rigot V, Cruet S, Andre F, Gauduchon P, Marvaldi J. Migration properties of the human ovarian adenocarcinoma cell line IGROV1: importance of alpha(v)beta3 integrins and vitronectin. Int J Cancer 1999; 80: 285-294 [PMID: 9935212]
44. Abu-Hijleh MF, Habbal OA, Moqattash ST. The role of the diaphragm in lymphatic absorption from the peritoneal cavity. J Anat 1995; 186 (Pt 3): 453-467 [PMID: 7559120]
45. Kusamura S, Baratti D, Zaffaroni N, Villa R, Laterza B, Balestra MR, Deraco M. Pathophysiology and biology of peritoneal carcinomatosis. World J Gastrointest Oncol 2010; 2: 12-18 [PMID: 21160812 DOI: 10.4251/wjgo.v2.i1.12]
46. Chu DZ, Lang NP, Thompson C, Osteen PK, Westbrook KC. Peritoneal carcinomatosis in nongynecologic malignancy. A prospective study of prognostic factors. Cancer 1989; 63: 364-367 [PMID: 2910444]
47. Köhne CH, Cunningham D, Di Costanzo F, Glimelius B, Blijham G, Aranda E, Scheithauer W, Rougier P, Palmer M, Wils J, Baron B, Pignatti F, Schöffski P, Micheel S, Hecker H. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13: 308-317 [PMID: 11886010]
48. Bloemendaal AL, Verwaal VJ, van Ruth S, Boot H, Zoetmulder FA. Conventional surgery and systemic chemotherapy for peritoneal carcinomatosis of colorectal origin: a prospective study. Eur J Surg Oncol 2005; 31: 1145-1151 [PMID: 16084051 DOI: 10.1016/j.ejso.2005.06.002]
49. Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21: 3737-3743 [PMID: 14551293 DOI: 10.1200/JCO.2003.04.187]
50. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts S. Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial. J Clin Oncol 2006; 24: 3347-3353 [PMID: 16849748 DOI: 10.1200/JCO.2006.06.1317]
51. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342 [PMID: 15175435 DOI: 10.1056/NEJMoa032691]
52. Franko J, Shi Q, Goldman CD, Pockaj BA, Nelson GD, Goldberg RM, Pitot HC, Grothey A, Alberts SR, Sargent DJ. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 2012; 30: 263-267 [PMID: 22162570 DOI: 10.1200/JCO.2011.37.1039]
53. Weisberger AS, Levine B, Storaasli JP. Use of nitrogen mustard in treatment of serous effusions of neoplastic origin. J Am Med Assoc 1955; 159: 1704-1707 [PMID: 13271133]
54. Hribaschek A, Meyer F, Schneider-Stock R, Pross M, Ridwelski K, Lippert H. Comparison of intraperitoneal with intravenous administration of taxol in experimental peritoneal carcinomatosis. Chemotherapy 2007; 53: 410-417 [PMID: 17952000 DOI: 10.1159/000110005]
55. Vaillant JC, Nordlinger B, Deuffic S, Arnaud JP, Pelissier E, Favre JP, Jaeck D, Fourtanier G, Grandjean JP, Marre P, Letoublon C. Adjuvant intraperitoneal 5-fluorouracil in high-risk colon cancer: A multicenter phase III trial. Ann Surg 2000; 231: 449-456 [PMID: 10749603]
56. Nordlinger B, Rougier P, Arnaud JP, Debois M, Wils J, Ollier JC, Grobost O, Lasser P, Wals J, Lacourt J, Seitz JF, Guimares dos Santos J, Bleiberg H, Mackiewickz R, Conroy T, Bouché O, Morin T, Baila L, van Cutsem E, Bedenne L. Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial. Lancet Oncol 2005; 6: 459-468 [PMID: 15992694 DOI: 10.1016/S1470-2045(05)70222-9]
57. Elias D, Delperro JR, Sideris L, Benhamou E, Pocard M, Baton O, Giovannini M, Lasser P. Treatment of peritoneal carcinomatosis from colorectal cancer: impact of complete cytoreductive surgery and difficulties in conducting randomized trials. Ann Surg Oncol 2004; 11: 518-521 [PMID: 15123461 DOI: 10.1245/ASO.2004.09.008]
58. Mahteme H, Hansson J, Berglund A, Pa˚hlman L, Glimelius B, Nygren P, Graf W. Improved survival in patients with peritoneal metastases from colorectal cancer: a preliminary study. Br J Cancer 2004; 90: 403-407 [PMID: 14735184 DOI: 10.1038/sj.bjc.6601586]
59. Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, Barone R, Yonemura Y, Cavaliere F, Quenet F, Gutman M, Tentes AA, Lorimier G, Bernard JL, Bereder JM, Porcheron J, Gomez-Portilla A, Shen P, Deraco M, Rat P. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004; 22: 3284-3292 [PMID: 15310771 DOI: 10.1200/JCO.2004.10.012]
60. Yan TD, Black D, Savady R, Sugarbaker PH. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 2006; 24: 4011-4019 [PMID: 16921055 DOI: 10.1200/JCO.2006.07.1142]
61. Verwaal VJ, van Ruth S, Witkamp A, Boot H, van Slooten G, Zoetmulder FA. Long-term survival of peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2005; 12: 65-71 [PMID: 15827780 DOI: 10.1007/s10434-004-1167-z]
62. Königsrainer I, Beckert S. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: where are we? World J Gastroenterol 2012; 18: 5317-5320 [PMID: 23082046 DOI: 10.3748/wjg.v18.i38.5317]
63. Al-Shammaa HA, Li Y, Yonemura Y. Current status and future strategies of cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. World J Gastroenterol 2008; 14: 1159-1166 [PMID: 18300340]
64. Coccolini F, Gheza F, Lotti M, Virzì S, Iusco D, Ghermandi C, Melotti R, Baiocchi G, Giulini SM, Ansaloni L, Catena F. Peritoneal carcinomatosis. World J Gastroenterol 2013; 19: 6979-6994 [PMID: 24222942 DOI: 10.3748/wjg.v19.i41.6979]
65. Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008; 15: 2426-2432 [PMID: 18521686 DOI: 10.1245/s10434-008-9966-2]
66. Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, Ferron G, Guilloit JM, Meeus P, Goéré D, Bonastre J. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol 2009; 27: 681-685 [PMID: 19103728 DOI: 10.1200/JCO.2008.19.7160]
67. Franko J, Ibrahim Z, Gusani NJ, Holtzman MP, Bartlett DL, Zeh HJ. Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer 2010; 116: 3756-3762 [PMID: 20564081 DOI: 10.1002/cncr.25116]
68. Elias D, Gilly F, Boutitie F, Quenet F, Bereder JM, Mansvelt B, Lorimier G, Dubè P, Glehen O. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol 2010; 28: 63-68 [PMID: 19917863 DOI: 10.1200/JCO.2009.23.9285]
69. Chua TC, Morris DL, Saxena A, Esquivel J, Liauw W, Doerfer J, Germer CT, Kerscher AG, Pelz JO. Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: a multicenter study. Ann Surg Oncol 2011; 18: 1560-1567 [PMID: 21203904 DOI: 10.1245/s10434-010-1522-1]
70. McConnell YJ, Mack LA, Francis WP, Ho T, Temple WJ. HIPEC + EPIC versus HIPEC-alone: differences in major complications following cytoreduction surgery for peritoneal malignancy. J Surg Oncol 2013; 107: 591-596 [PMID: 23129533 DOI: 10.1002/jso.23276]
71. Sugarbaker PH, Jablonski KA. Prognostic features of 51 colorectal and 130 appendiceal cancer patients with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Ann Surg 1995; 221: 124-132 [PMID: 7857141]
72. Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996; 82: 359-374 [PMID: 8849962]
73. Kianmanesh R, Scaringi S, Sabate JM, Castel B, Pons-Kerjean N, Coffin B, Hay JM, Flamant Y, Msika S. Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases. Ann Surg 2007; 245: 597-603 [PMID: 17414609 DOI: 10.1097/01.sla.0000255561.87771.11]
74. Glehen O, Cotte E, Schreiber V, Sayag-Beaujard AC, Vignal J, Gilly FN. Intraperitoneal chemohyperthermia and attempted cytoreductive surgery in patients with peritoneal carcinomatosis of colorectal origin. Br J Surg 2004; 91: 747-754 [PMID: 15164446 DOI: 10.1002/bjs.4473]
75. Portilla AG, Shigeki K, Dario B, Marcello D. The intraoperative staging systems in the management of peritoneal surface malignancy. J Surg Oncol 2008; 98: 228-231 [PMID: 18726882 DOI: 10.1002/jso.21068]
76. Rivard JD, McConnell YJ, Temple WJ, Mack LA. Cytoreduction and heated intraperitoneal chemotherapy for colorectal cancer: are we excluding patients who may benefit? J Surg Oncol 2014; 109: 104-109 [PMID: 24449172 DOI: 10.1002/jso.23446]
77. Gusani NJ, Cho SW, Colovos C, Seo S, Franko J, Richard SD, Edwards RP, Brown CK, Holtzman MP, Zeh HJ, Bartlett DL. Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. Ann Surg Oncol 2008; 15: 754-763 [PMID: 18080166 DOI: 10.1245/s10434-007-9701-4]
78. Segelman J, Akre O, Gustafsson UO, Bottai M, Martling A. Individualized prediction of risk of metachronous peritoneal carcinomatosis from colorectal cancer. Colorectal Dis 2014; 16: 359-367 [PMID: 24410859 DOI: 10.1111/codi.12552]
79. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E, Ciuleanu T, Wimberger P, Schmittel A, Schmalfeldt B, Burges A, Bokemeyer C, Lindhofer H, Lahr A, Parsons SL. The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer 2010; 127: 2209-2221 [PMID: 20473913 DOI: 10.1002/ijc.25423]
80. Ströhlein MA, Lordick F, Rüttinger D, Grützner KU, Schemanski OC, Jäger M, Lindhofer H, Hennig M, Jauch KW, Peschel C, Heiss MM. Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial. Onkologie 2011; 34: 101-108 [PMID: 21358214 DOI: 10.1159/000324667]